Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020182517 - CANCER DIAGNOSIS AND PROGNOSIS

Publication Number WO/2020/182517
Publication Date 17.09.2020
International Application No. PCT/EP2020/055437
International Filing Date 02.03.2020
IPC
C12Q 1/6886 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
CPC
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/112
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
112Disease subtyping, staging or classification
C12Q 2600/118
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
118Prognosis of disease development
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
Applicants
  • ONCOLAB DIAGNOSTICS GMBH [AT]/[AT]
Inventors
  • ZEILLINGER, Robert
  • OBERMAYR, Eva
  • HAMILTON, Gerhard
Agents
  • REDL, Gerda
  • LOIDL, Manuela
  • GASSNER, Birgitta
Priority Data
19161742.208.03.2019EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CANCER DIAGNOSIS AND PROGNOSIS
(FR) DIAGNOSTIC ET PRONOSTIC DE CANCER
Abstract
(EN)
A method of identifying an SCLC patient at risk of disease progression comprising determining the expression of at least one marker selected from a neuroendocrine marker and/or DLLS in a blood sample or blood sample fraction of said patient, wherein said at least one marker is indicative of the patient's prognosis.
(FR)
L'invention concerne une méthode d'identification d'un patient souffrant d'un SCLC par rapport à un risque de progression d'une maladie, consistant à déterminer l'expression d'au moins un marqueur choisi parmi un marqueur neuroendocrinien et/ou un DLLS dans un échantillon de sang ou dans une fraction d'échantillon de sang dudit patient, ledit ou lesdits marqueurs indiquant le pronostic du patient.
Latest bibliographic data on file with the International Bureau